All company structures are involved at different levels in the drug manufacturing process...
Introduction
The data related to the professional collaboration between Menarini Hellas and Healthcare Professionals (HCPs), Healthcare Organizations (HCOs), as well as research and development activities for the year 2023, will be available on the Menarini Hellas website as of June 30, 2024.
Absolute transparency through the publication of this data represents the objective and clear choice of pharmaceutical companies. Transparency is essential for building trust between the pharmaceutical industry, the medical community, and civil society.
Professional collaboration between pharmaceutical companies and healthcare professionals takes place across various areas of activity:
1. Research and development of new drugs, through clinical trials conducted in hospitals, universities, and public or private healthcare organizations.
2. Consulting services.
3. Scientific seminars and conferences providing information and updates.
4. Scientific events, conferences, and Continuing Medical Education (CME) courses organized by public bodies, universities, scientific societies, and accredited CME providers.
Disclosure by MENARINI HELLAS of benefits in accordance with the provisions of Article 66, paragraph 7a of Law 4316/2014, the Code of Disclosure of the Hellenic Association of Pharmaceutical Companies (SFEE), and the EFPIA Disclosure Code.
According to the legislative framework (Law 4316 [Government Gazette 270A/24.12.2014, Article 66, paragraph 7(a)]), pharmaceutical companies in Greece are required to disclose, on an individual basis per recipient, any benefits granted to Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs). Additionally, the EFPIA Disclosure Code and the SFEE Disclosure Code require their members to disclose payments and benefits to HCPs and HCOs.
It is explicitly noted that in Greece, this disclosure was shaped following the issuance of Opinions No. 05/2016 and 02/2017 by the Hellenic Data Protection Authority, the content of which limits nominal disclosure to scientific promotional events, as well as the relevant announcement by the National Organization for Medicines (EOF), which was published on the EOF website on 01/04/2021 as follows:
Disclosure of benefits for the scientific events of 2021 Within the framework of implementing paragraph 7 of Article 66 of Law 4316/2014 (A' 270), regarding the obligation of disclosure, any request for event organization, HCP participation, and expert committees submitted to the platform and carried out during 2020 must have been accounted for electronically by EOF-regulated product companies and scientific bodies by 30.06.2021, in order to proceed with the disclosure of this data.
It is emphasized that in EOF's online application for scientific conferences, the "Expense Report" service has been activated for 2020. This service records, cumulatively per HCP or HCO, all expense types covered under paragraph 7 of
Article 66 of Law 4316/2014 (A' 270) and not included in the reports for: (a) "Event Organization Report," (b) "Committee Organization Report," and (c) "HCP Participation Report." It is underlined that the above-mentioned deadline will be strictly observed.
The Management of the National Organization for Medicines (EOF)
Regarding the submission of data to EOF, Menarini Hellas intends to submit the required data in full compliance with the above announcement.
In light of the above, we disclose on the corporate website, for the period from 01/01/2022 to 31/12/2022, as follows:
· On an individual basis per recipient, every benefit to HCPs for promotional events.
· Collectively, all other benefits to HCPs.
· Individually, benefits to HCOs.
· Collectively, benefits related to Research and Development activities, as well as non-interventional studies.
· Individually/detailed, support (financial or indirect non-financial) to Patient Associations (PAs).
In any case, this disclosure aims to enhance transparency and professional ethics in the relationships between pharmaceutical companies, HCPs, and HCOs, as well as to safeguard the right of patients and society to know about the relationship between pharmaceutical companies and the scientific community.